This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The second-quarter earnings season just started in the U.S., and while the initial reads have shown strong growth for both profits and revenue, such results may not be enough to power the market out of the range it has been stuck in for months.
WFCNP C.WSA MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS C C.PRL C.PRJ C.PRK C.PRG C.PRC MS.PRI C.PRPCL MS.PRK CGBBW
More positive: An investor monitoring stock prices in the gallery of the RHB Investment Bank Bhd headquarters yesterday. Bursa Malaysia opened higher as the positive performance of Wall Street last Friday spilled over to the local bourse, which boosted investors’ risk appetite. — Bernama
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX BSMAF WFC.PRW WFC.PRV 1818
Shares of Charles Schwab (SCHW - Free Report) popped nearly 1% during regular trading hours Monday, just one day before the financial services firm is set to release its latest quarterly financial results. Let’s see what investors should expect.
WFC SCHW.PRBCL WFCNP WFC.WS C WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Starting Tuesday, Juul e-cigarettes will be available in England and Scotland. Juul's first international market was Israel, where it launched in February.
WFC WFCNP IMBBY WFC.WS JAPAF WFC.PRL 2914 WFC.PRJ BATS 4162 ITYBF WFC.PRT WFC.PRR WFC.PRQ JAPAY WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV IMBBF
Three of the largest banks in the U.S. posted earnings reports on Friday and for the most part all three disappointed investors. In an article posted on Wednesday of last week, I had suggested that there was little to like about Citigroup, JPMorgan Chase, or Wells Fargo ahead of those reports. The fundamentals were just slightly above average, the sentiment was mostly bullishly skewed, and only JPMorgan Chase had a decent looking chart.
WFC WFCNP WFC.WS CMA WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Millennials aren't the defining factor in Bank of America's mobile banking strength, which grew by 11 percent in the second quarter to 25.3 million active users, Chairman and CEO Brian Moynihan told CNBC on Monday.
WFC WFCNP WFC.WS MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT WFC.PRR WFC.PRQ MS.PRI WFC.PRP WFC.PRO WFC.PRN MS.PRK WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV
NEW YORK, July 16 (Reuters) - Slowly but surely, depositors are starting to shift money from basic U.S. bank accounts to products that pay more than a sliver of a percent in interest.
WFCNP C.WSA WFC.PRL WFC.PRJ WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS C C.PRL PNC.PRP C.PRJ PNC.PRQ C.PRK PNCFO C.PRG C.PRC PNC.WS C.PRPCL CGBBW PNC PNUCL
Earnings season is now in full session after JP Morgan (JPM - Free Report) and Citigroup (C - Free Report) beat earnings on Friday while Wells Fargo (WFC - Free Report) stumbled. Bank of America (BAC - Free Report) and Blackstone (BLK - Free Report) were the headliners on Monday, both surpassing expectations and boosting investor confidence.
WFCNP MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN MS WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS BAC C MS.PRI MS.PRK
Financials surged on Monday following strong Bank of America earnings, with peers such as Citigroup, Wells Fargo and Goldman Sachs rallying on the day. As investors navigate the onslaught of big bank reports and volatility in the financial sector, some market watchers are anticipating further upside ahead.
WFC WFCNP WFC.WS MS.PRE WFC.PRL DTK MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT WFC.PRR WFC.PRQ MS.PRI WFC.PRP WFC.PRO WFC.PRN MS.PRK WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV
Americans can be forgiven for forgetting what happened last week, let alone six years ago given today’s media blitz on all things Donald Trump. But it is worth remembering Obama-era abuses of power that, far from this week’s headlines, are having their day in court.
WFCNP WFC.PRL WFC.PRJ FNMA FMCKI WFC.PRT FMCKJ WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL FMCC FMCCS FMCCT
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Markets closed higher on Friday, with the S&P 500 posting its highest close in more than five months. The Dow too reclaimed its 25,000 mark for the first time in almost a month. The rally was led by tech and industrial stocks, which offset a decline in financial stocks, as results from three of the major banks failed to boost investors’ confidence.
WFCNP FB MTSI C.WSA CAT WBA WFC.PRL WFC.PRJ WFC.PRT C.WS.B WFC.PRR WFC.PRQ AMZN WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS C CATR C.PRL C.PRJ C.PRK UTX C.PRG C.PRC GTT C.PRPCL CGBBW MSFT
Despite dismal investment banking performance, loan growth, better-than-expected trading activities and tax cuts drove Bank of America’s (BAC - Free Report) second-quarter 2018 earnings of 63 cents per share, which handily outpaced the Zacks Consensus Estimate of 57 cents. Also, the figure was 43% higher than the prior-year quarter. Shares of BofA rose nearly 1.2% in the pre-market trading, indicating that investors have taken the results in their stride.
WFC WFCNP WFC.WS BAC C NTRSP WFC.PRL WFC.PRJ BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP NTRS GTT WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Bank of America reported 2Q18 results that were strong across the board, with mild weakness in investment banking as the one outlier.
WFC WFCNP WFC.WS BAC WFC.PRL WFC.PRJ BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Chicago, IL – July 16, 2018 – Zacks.com releases the list of companies likely to issue earnings surprises. This week’s list includes Wells Fargo (WFC - Free Report) , JPMorgan (JPM - Free Report) , Bank of America (BAC - Free Report) , Goldman Sachs (GS - Free Report) and Morgan Stanley (MS - Free Report) .
WFCNP RM MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA FITBI ETM BAC WFC.PRT MTCH WFC.PRR ROSEU WFC.PRQ WFC.PRP WFC.PRO WFC.PRN MS WFC.PRY PAA WFC.PRX WFC.PRW NMM WFC.PRV ROSE WFC WFC.WS BAC AMC ETM.WI MS.PRI GTT MS.PRK FITB
4h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
5h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET